Outcome of Boston Type I Keratoprosthesis in a Tertiary Eye Center in Erbil City
DOI:
https://doi.org/10.56056/amj.2025.389Keywords:
Boston Type I keratoprosthesis, Corneal disease, Visual acuityAbstract
Background and objective: The corneal diseases constituted the fourth leading cause of blindness in Iraq. Boston keratoprosthesis implanting is considered as effective surgical management of corneal diseases. The objective is to determine the visual outcome of Boston Type I keratoprosthesis in a tertiary eye center in Erbil city.
Methods: Present study was a retrospective cross-sectional study carried out in Tertiary Eye center (North Eye center) in Erbil city-Kurdistan region/Iraq through the period of seven years from 1st of May 2017, to 30th of April 2023 on sample of 37 patients underwent Boston Type I Keratoprosthesis surgery. All the surgeries and postoperative evaluation were implemented by Dr. Didar S. Anwar. Patients examined by slitlamp device both pre and postoperatively, all the findings were recorded on patients’ sheet and the data were evaluated. Visual acuity was done by (Refractionist & optometrist).
Results: The mean age of patients was (50.1 years) with predominance of male gender. Preoperative visual acuity was poor (non-useful) for all studied patients. Postoperative visual acuity of patients was distributed as followings; poor (non-useful) in 37.8% of patients, poor (useful) in 13.5% of patients, borderline in 24.3% of patients and good in 24.3% of patients. There was a highly significant difference in visual acuity between pre and postoperative Boston Type I keratoprosthesis (p<0.001), the visual acuity was significantly improved postoperatively. The postoperative complications were reported for 59.5% of patients; commonly retro prosthetic membrane.
Conclusions: The Boston Type I keratoprosthesis implantation is effective and relatively safe surgery with a prominent improvement in visual acuity.
Downloads
References
1. Kim MJ, Bakhtiari P, Aldave AJ. The international use of the Boston Type I keratoprosthesis. Int Ophthalmol Clin 2013; 53(2):79-89.
2. Al-Shakarchi FI. Blindness in iraq: leading causes, target patients, and barriers to treatment. Middle East Afr J Ophthalmol 2011; 18(3):199-203.
3. Oliva MS, Schottman T, Gulati M. Turning the tide of corneal blindness. Indian J Ophthalmol 2012; 60(5):423-427.
4. Avadhanam VS, Smith HE, Liu C. Keratoprostheses for corneal blindness: a review of contemporary devices. Clin Ophthalmol 2015; 9:697-720.
5. Avadhanam VS, Liu CS. A brief review of Boston Type-1 and osteo-odonto keratoprostheses. Br J Ophthalmol 2015; 99(7):878-887.
6. Traish AS, Chodosh J. Expanding application of the Boston Type I keratoprosthesis due to advances in design and improved post-operative therapeutic strategies. Semin Ophthalmol 2010; 25(5-6):239-243.
7. Zarei-Ghanavati M, Liu C. Keratoprosthesis: Current Choices and Future Development. Asia Pac J Ophthalmol (Phila) 2019; 8(6):429-431.
8. Nonpassopon M, Niparugs M, Cortina MS. Boston Type 1 Keratoprosthesis: Updated Perspectives. Clin Ophthalmol 2020; 14:1189-1200.
9. Driver TH, Aravena C, Duong HNV, Christenbury JG, Yu F, Basak SK, et al. Outcomes of the Boston Type I Keratoprosthesis as the Primary Penetrating Corneal Procedure. Cornea 2018; 37(11):1400-1407.
10. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston Type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009; 116(4):640-651.
11. Ciolino JB, Belin MW, Todani A, Al-Arfaj K, Rudnisky CJ; Boston Keratoprosthesis Type 1 Study Group. Retention of the Boston keratoprosthesis Type 1: multicenter study results. Ophthalmology 2013; 120(6):1195-200.
12. Chang HY, Luo ZK, Chodosh J, Dohlman CH, Colby KA. Primary implantation of Type I Boston keratoprosthesis in nonautoimmune corneal diseases. Cornea 2015; 34(3):264–270.
13. Srikumaran D, Munoz B, Aldave AJ. Long-term outcomes of boston Type 1 keratoprosthesis implantation: a retrospective multicenter cohort. Ophthalmology 2014; 121(11):2159–2164.
14. Aravena C, Bozkurt TK, Yu F, Aldave AJ. Long-term outcomes of the Boston Type I keratoprosthesis in the management of corneal limbal stem cell deficiency. Cornea 2016; 35(9):1156–1164.
15. Shanbhag SS, Saeed HN, Paschalis EI, Chodosh J. Boston keratoprosthesis Type 1 for limbal stem cell deficiency after severe chemical corneal injury: a systematic review. Ocul Surf 2018; 16(3):272–281.
16. Palioura S, Kim B, Dohlman CH, Chodosh J. The Boston keratoprosthesis Type I in mucous membrane pemphigoid. Cornea 2013; 32(7):956–961.
17. Fry M, Aravena C, Yu F, Kattan J, Aldave AJ. Long-term outcomes of the Boston Type I keratoprosthesis in eyes with previous herpes simplex virus keratitis. Br J Ophthalmol 2018; 102(1):48–53.
18. Brown CR, Wagoner MD, Welder JD. Boston keratoprosthesis Type 1 for herpes simplex and herpes zoster keratopathy. Cornea 2014; 33(8):801–805.
19. Rudnisky CJ, Belin MW, Todani A. Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis Type 1: multicenter study results. Ophthalmology 2012; 119(5):951–955.
20. Ali MH, Dikopf MS, Finder AG. Assessment of glaucomatous damage after Boston keratoprosthesis implantation based on digital planimetric quantification of visual fields and optic nerve head imaging. Cornea 2018; 37(5):602–608.
21. Shihadeh WA, Mohidat HM. Outcomes of the Boston keratoprosthesis in jordan. Middle East Afr J Ophthalmol 2012; 19(1):97-100.
22. Kamyar R, Weizer JS, de Paula FH, Stein JD, Moroi SE, John D, et al. Glaucoma associated with Boston Type I keratoprosthesis. Cornea 2012; 31(2):134-139.
23. AlHilali SM, Al-Swailem SA. Challenges of Glaucoma Management in Patients with Type I Boston Keratoprosthesis. Clin Ophthalmol 2022; 16:369-374.
24. Patel AP, Wu EI, Ritterband DC, Seedor JA. Boston Type 1 keratoprosthesis: the New York Eye and Ear experience. Eye (Lond) 2012; 26(3):418-425.
25. Gao M, Chen Y, Wang J, Wang C. Post-operative outcomes associated with Boston Type 1 keratoprosthesis implantation in Northeast China. Exp Ther Med 2019; 17(1):869-873.
26. Jardeleza MS, Rheaume MA, Chodosh J, Lane AM, Dohlman CH. Retinal detachments after Boston Keratoprosthesis: incidence, predisposing factors, and visual outcomes. Digit J Ophthalmol 2015; 21(4):1-15.
27. Al Arfaj K, Hantera M. Short-term visual outcomes of Boston keratoprosthesis Type I in saudi arabia. Middle East Afr J Ophthalmol 2012; 19(1):88-92.
28. Wang JC, Rudnisky CJ, Belin MW, Ciolino JB; Boston Type 1 Keratoprosthesis Study Group. Outcomes of Boston keratoprosthesis Type 1 reimplantation: multicentre study results. Can J Ophthalmol 2018; 53(3):284-290.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Harem Kamal Khidher, Didar Sddeq Anwar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
